FundedIQ
Biotechnology

Anteris Technologies: Funding, Investors & Team (Sep 2026)

Aortic stenosis patients and their doctors face several challenges, and Anteris Technologies, a structural heart firm, is working to find novel solutions. Younger patients who require a lifelong heart valve should use our DurAVRTM Transcatheter Heart Valve (THV) System. Unique, single-piece DurAVRTM THV valve duplicates the normal blood flow of a healthy human aortic valve through first-in-class biomimetic design. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

anteristech.com LinkedIn Toowong, Australia 101-250 employees
Total raised
$24.3M
Rounds
1
Latest
Undisclosed round
Feb 2023

Anteris Technologies has raised $24.3M across 1 funding round on record, the most recent an undisclosed round of $24.3M announced in Feb 2023.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Anteris Technologies Company Profile and Key Stats

Total funding raised
$24.3M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$24.3M in Feb 2023
Employees
101-250
reported band
Headquarters
Toowong, Australia

Latest funding round on record: Feb 2023.

Anteris Technologies Funding Rounds

Date
Round
Amount
Undisclosed round
$24.3M

Anteris Technologies Founders and Leadership Team

Name
Role
Contact
Wayne Paterson
CEO
Locked

Contact details for the Anteris Technologies team: 1 of 1 has an email address on file.

Start 14-day free trial →

Anteris Technologies Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,156
$4.0M

Anteris Technologies' latest round of $24.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Anteris Technologies in Biotechnology and Toowong

Companies Similar to Anteris Technologies

AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…

Series D $315M

The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…

Seed $2.0M

Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…

Undisclosed round $50.0M

Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…

Undisclosed round $3.5M

Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…

Undisclosed round $990k

Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…

Undisclosed round $10.1M

Imugene is a publicly-listed biotechnology company with operations in America and Europe,

Undisclosed round $8.6M

BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology

Undisclosed round $10.8M

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…

Undisclosed round $600M

Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…

Series A $13.3M

HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…

Undisclosed round $1.4M

Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…

Undisclosed round $320k

Anteris Technologies Funding FAQs

What does Anteris Technologies do?

Aortic stenosis patients and their doctors face several challenges, and Anteris Technologies, a structural heart firm, is working to find novel solutions. Younger patients who require a lifelong heart valve should use our DurAVRTM Transcatheter Heart Valve (THV) System. Unique, single-piece DurAVRTM THV valve duplicates the normal blood flow of a healthy human aortic valve through first-in-class biomimetic design. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

How much funding has Anteris Technologies raised?

Anteris Technologies has raised $24.3M across 1 round on record. The most recent is an undisclosed round of $24.3M announced in Feb 2023.

When did Anteris Technologies last raise funding?

Anteris Technologies' most recent funding round on record is an undisclosed round of $24.3M, announced in Feb 2023.

Who is the CEO of Anteris Technologies?

Wayne Paterson is listed as CEO at Anteris Technologies.

Where is Anteris Technologies headquartered?

Anteris Technologies is based in Toowong, Queensland, Australia.

How many employees does Anteris Technologies have?

Anteris Technologies is in the 101-250 employee band.

How does Anteris Technologies' funding compare to other Biotechnology startups?

Anteris Technologies' latest round of $24.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Anteris Technologies Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Anteris Technologies is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.